Analyzing the Advancing Applications for Next-Generation Sequencing in Lung Cancer
Drs Brown and Husain discuss the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by NeoGenomics, we had the pleasure of speaking with Shari Brown, MD, director of molecular pathology services at NeoGenomics, and Hatim Husain, MD, an associate professor of medicine at UC San Diego Health, to discuss the current role of next-generation sequencing in lung cancer.
In our exclusive interview, Brown and Hussain discussed the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.
